Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study.
Fiche publication
Date publication
juillet 2001
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier
Tous les auteurs :
Quoix E, Breton JL, Daniel C, Jacoulet P, Debieuvre D, Paillot N, Kessler R, Moreau L, Coëtmeur D, Lemarié E, Milleron B
Lien Pubmed
Résumé
Although the average age of lung cancer patients is increasing, many elderly patients remain undertreated, mainly because of the fear of higher treatment toxicity in this category of patients. We conducted a study to evaluate the efficacy and tolerability of a combination therapy with carboplatin (C) and etoposide phosphate (EP) in elderly patients with Small-Cell Lung Cancer (SCLC).
Mots clés
Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Carboplatin, administration & dosage, Carcinoma, Small Cell, drug therapy, Etoposide, administration & dosage, Female, Humans, Lung Neoplasms, drug therapy, Male, Organophosphorus Compounds, administration & dosage, Survival Analysis, Treatment Outcome
Référence
Ann. Oncol.. 2001 Jul;12(7):957-62